Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229677 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL2033787 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL20299891 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29989746 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL30082405 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29401317 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL13946516 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL14940666 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL1253102 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 | |
| SCHEMBL29989676 | 0.91 | CASP3 (0.54) | MDM4TP53CASP3KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2026-03-12 | — | — | US | disclosed |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | MARIANA ONCOLOGY INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MARIANA ONCOLOGY INC (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4570317-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2025-06-18 | — | — | EP | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4499667-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-12-12 | — | — | US | disclosed |
| US-20240360178-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-20190352256-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190352256-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | INTERVET INC. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3558939-A1 | COMPOUNDS USEFUL FOR TREATING A MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI INFECTION | Intervet International B.V. (NL) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558284-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | Intervet International B.V. (NL) | 2019-10-30 | — | — | EP | disclosed |
| US-20180296688-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | SIRENAS LLC | 2018-10-18 | — | — | US | disclosed |
| WO-2018115432-A2 | COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE | INTERVET INTERNATIONAL B.V. (NL) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018115421-A1 | COMPOUNDS USEFUL FOR TREATING A MANNHEIMIA HAEMOLYTICA OR HISTOPHILUS SOMNI INFECTION | INTERVET INTERNATIONAL B.V. (NL) | 2018-06-28 | — | — | WO | disclosed |
| EP-1047708-B1 | PEPTIDE CHELATORS THAT PREDOMINATELY FORM A SINGLE STEREOISOMERIC SPECIES UPON COORDINATION TO A METAL CENTER | BRACCO INT BV (NL) | 2007-09-26 | — | — | EP | disclosed |
| EP-1047708-A1 | PEPTIDE CHELATORS THAT PREDOMINATELY FORM A SINGLE STEREOISOMERIC SPECIES UPON COORDINATION TO A METAL CENTER | RESOLUTION PHARMACEUTICALS INC. (CA) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999033863-A1 | PEPTIDE CHELATORS THAT PREDOMINATELY FORM A SINGLE STEREOISOMERIC SPECIES UPON COORDINATION TO A METAL CENTER | RESOLUTION PHARMACEUTICALS INC. (CA) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1009/4885TP53 127/4885CASP3 1714/4885 |
| US-20260070945-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MDM4 2686/4885TP53 428/4885CASP3 1567/4885 |
| US-20250296959-A1 | B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | CD274, CD44, CD74 | MDM4 2014/4885TP53 119/4885CASP3 2086/4885 |
| US-20250205373-A1 | ENRICHED AND STABLE RADIOLIGAND THERAPY FORMULATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | ASGR1, GPR119, LDLR | MDM4 1905/4885TP53 42/4885CASP3 4534/4885 |
| US-20240360178-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885CASP3 1798/4885 |
| US-20240409585-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1149/4885TP53 154/4885CASP3 1646/4885 |
| US-20190352256-A1 | Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection | HEXD, SORD, SDHA | MDM4 3080/4885TP53 3448/4885CASP3 2879/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885CASP3 1798/4885 |
| US-20180296688-A1 | ANTI-CANCER COMPOUNDS AND CONJUGATES THEREOF | DDOST, DGKG, DGKB | MDM4 1183/4885TP53 102/4885CASP3 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.